BACKGROUND AND PURPOSE: Systemic oxidative stress associated with dietary calorie overload plays an important role in the deterioration of vascular function in middle-aged patients suffering from obesity and insulin resistance. However, effective therapy is still lacking. EXPERIMENTAL APPROACH: In this study, we used a mouse model of middle-aged obesity to investigate the therapeutic potential of pharmaceutical inhibition (apocynin, 5 mM supplied in the drinking water) or knockout of Nox2, an enzyme generating reactive oxygen species (ROS), in high-fat diet (HFD)-induced obesity, oxidative stress, insulin resistance and endothelial dysfunction. Littermates of C57BL/6J wild-type (WT) and Nox2 knockout (KO) mice (7 months old) were fed with a HFD (45% kcal fat) or normal chow diet (NCD, 12% kcal fat) for 16 weeks and used at 11 months of age. KEY RESULTS: Compared to NCD WT mice, HFD WT mice developed obesity, insulin resistance, dyslipidaemia and hypertension. Aortic vessels from these mice showed significantly increased Nox2 expression and ROS production, accompanied by significantly increased ERK1/2 activation, reduced insulin receptor expression, decreased Akt and eNOS phosphorylation and impaired endothelium-dependent vessel relaxation to acetylcholine. All these HFD-induced abnormalities (except the hyperinsulinaemia) were absent in apocynin-treated WT or Nox2 KO mice given the same HFD. CONCLUSIONS AND IMPLICATIONS: In conclusion, Nox2-derived ROS played a key role in damaging insulin receptor and endothelial function in dietary obesity after middle-age. Targeting Nox2 could represent a valuable therapeutic strategy in the metabolic syndrome.
BACKGROUND AND PURPOSE: Systemic oxidative stress associated with dietary calorie overload plays an important role in the deterioration of vascular function in middle-aged patients suffering from obesity and insulin resistance. However, effective therapy is still lacking. EXPERIMENTAL APPROACH: In this study, we used a mouse model of middle-aged obesity to investigate the therapeutic potential of pharmaceutical inhibition (apocynin, 5 mM supplied in the drinking water) or knockout of Nox2, an enzyme generating reactive oxygen species (ROS), in high-fat diet (HFD)-induced obesity, oxidative stress, insulin resistance and endothelial dysfunction. Littermates of C57BL/6J wild-type (WT) and Nox2 knockout (KO) mice (7 months old) were fed with a HFD (45% kcal fat) or normal chow diet (NCD, 12% kcal fat) for 16 weeks and used at 11 months of age. KEY RESULTS: Compared to NCD WT mice, HFD WTmice developed obesity, insulin resistance, dyslipidaemia and hypertension. Aortic vessels from these mice showed significantly increased Nox2 expression and ROS production, accompanied by significantly increased ERK1/2 activation, reduced insulin receptor expression, decreased Akt and eNOS phosphorylation and impaired endothelium-dependent vessel relaxation to acetylcholine. All these HFD-induced abnormalities (except the hyperinsulinaemia) were absent in apocynin-treated WT or Nox2 KO mice given the same HFD. CONCLUSIONS AND IMPLICATIONS: In conclusion, Nox2-derived ROS played a key role in damaging insulin receptor and endothelial function in dietary obesity after middle-age. Targeting Nox2 could represent a valuable therapeutic strategy in the metabolic syndrome.
Authors: J David Symons; Shawna L McMillin; Christian Riehle; Jason Tanner; Milda Palionyte; Elaine Hillas; Deborah Jones; Robert C Cooksey; Morris J Birnbaum; Donald A McClain; Quan-Jiang Zhang; Derrick Gale; Lloyd J Wilson; E Dale Abel Journal: Circ Res Date: 2009-04-02 Impact factor: 17.367
Authors: Francesco Violi; Valerio Sanguigni; Roberto Carnevale; Alessandro Plebani; Paolo Rossi; Andrea Finocchi; Claudio Pignata; Domenico De Mattia; Baldassarre Martire; Maria Cristina Pietrogrande; Silvana Martino; Eleonora Gambineri; Anna Rosa Soresina; Pasquale Pignatelli; Francesco Martino; Stefania Basili; Lorenzo Loffredo Journal: Circulation Date: 2009-10-05 Impact factor: 29.690
Authors: Sabine Heumüller; Sven Wind; Eduardo Barbosa-Sicard; Harald H H W Schmidt; Rudi Busse; Katrin Schröder; Ralf P Brandes Journal: Hypertension Date: 2007-12-17 Impact factor: 10.190
Authors: Steven J Forrester; Daniel S Kikuchi; Marina S Hernandes; Qian Xu; Kathy K Griendling Journal: Circ Res Date: 2018-03-16 Impact factor: 17.367
Authors: Matthew R DiStasi; Julie A Mund; H Glenn Bohlen; Steven J Miller; David A Ingram; Michael C Dalsing; Joseph L Unthank Journal: Am J Physiol Heart Circ Physiol Date: 2015-08-21 Impact factor: 4.733
Authors: Kristoffer Rosenstand; Kenneth Andersen; Rasmus Terp; Peter Gennemark; Ditte Gry Ellman; Anna Reznichenko; Kate Lykke Lambertsen; Paul M Vanhoutte; Pernille B L Hansen; Per Svenningsen Journal: J Physiol Biochem Date: 2020-02-03 Impact factor: 4.158
Authors: Guy Eelen; Pauline de Zeeuw; Lucas Treps; Ulrike Harjes; Brian W Wong; Peter Carmeliet Journal: Physiol Rev Date: 2018-01-01 Impact factor: 37.312
Authors: Petra Haberzettl; James P McCracken; Aruni Bhatnagar; Daniel J Conklin Journal: Am J Physiol Heart Circ Physiol Date: 2016-03-25 Impact factor: 4.733
Authors: Carlos Henríquez-Olguín; Susanna Boronat; Claudio Cabello-Verrugio; Enrique Jaimovich; Elena Hidalgo; Thomas E Jensen Journal: Antioxid Redox Signal Date: 2019-11-01 Impact factor: 8.401